Investors Reminded of Class Action Deadline Against ImmunityBio for Claims Exceeding $100,000

Class Action Notice for ImmunityBio Investors

Overview

Recent developments have brought significant attention to ImmunityBio, Inc. (NASDAQ: IBRX) as shareholders prepare for a potential class action lawsuit. ClaimsFiler, a renowned shareholder information service, urges investors with losses exceeding $100,000 to pay attention to an important deadline. Those wishing to file lead plaintiff applications must act by May 26, 2026.

This lawsuit stems from the company’s alleged failure to disclose crucial information during a specific period when its stock was trading, raising concerns over investor rights and corporate transparency. The legal action is currently set in the United States District Court for California.

Timeline and Background

The timeline of key events began with a substantial price drop in ImmunityBio's shares. On March 24, 2026, a letter from the U.S. Food and Drug Administration (FDA) regarding violations in the promotion of Anktiva—an important treatment for bladder cancer—emerged publicly. The FDA letter, which stated that the company's promotional materials misrepresented Anktiva, was highlighted as a major turning point. The fallout from this communication resulted in the stock losing 21% of its value, plummeting from $9.40 to $7.42 per share within hours.

This event triggered widespread concern among investors, as the letter warned of misleading implications suggesting Anktiva could cure all cancers, violating both the Federal Food, Drug, and Cosmetic Act.

Implications for Shareholders

As the lawsuit progresses, lots of hope rests on the lead plaintiff role, which allows designated shareholders to represent the interests of the entire class. Investors are being encouraged to step forward if they had purchased or otherwise acquired ImmunityBio's securities from January 19, 2026, to March 24, 2026. By participating, they can potentially reclaim some of their losses from the company's alleged negligence.

Taking Action

Interested parties can find further information and resources by visiting ClaimsFiler's dedicated page at claimsfiler.com or by contacting them toll-free at 844-367-9658. Legal representatives from Kahn Swick & Foti, LLC are available for discussions regarding your claims.

About ClaimsFiler

ClaimsFiler is dedicated to aiding retail investors in recovering significant amounts from securities class action settlements. It offers various services, allowing investors to register for free, and access important information and websites concerning class action cases. Moreover, users can upload portfolio transactional data to stay informed about pertinent securities cases that may impact their interests.

In conclusion, the ongoing class action against ImmunityBio represents an important battleground for many investors who believe they have been wronged. As deadlines approach, swift action will be paramount to ensuring their rights are protected, and potential losses mitigated. To remain updated, investors are encouraged to act promptly to secure their positions in this developing case.